596 related articles for article (PubMed ID: 11352962)
1. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor.
Sung KW; Yoo KH; Cho EJ; Koo HH; Lim DH; Shin HJ; Ahn SD; Ra YS; Choi ES; Ghim TT
Pediatr Blood Cancer; 2007 Apr; 48(4):408-15. PubMed ID: 17066462
[TBL] [Abstract][Full Text] [Related]
3. Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy.
Prados MD; Wara W; Edwards MS; Ater J; Rabbit J; Lamborn K; Davis R; Levin VA
Pediatr Neurosurg; 1996 Oct; 25(4):174-81. PubMed ID: 9293544
[TBL] [Abstract][Full Text] [Related]
4. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors.
Allen JC; Donahue B; DaRosso R; Nirenberg A
Int J Radiat Oncol Biol Phys; 1996 Dec; 36(5):1155-61. PubMed ID: 8985038
[TBL] [Abstract][Full Text] [Related]
7. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience.
Fangusaro J; Finlay J; Sposto R; Ji L; Saly M; Zacharoulis S; Asgharzadeh S; Abromowitch M; Olshefski R; Halpern S; Dubowy R; Comito M; Diez B; Kellie S; Hukin J; Rosenblum M; Dunkel I; Miller DC; Allen J; Gardner S
Pediatr Blood Cancer; 2008 Feb; 50(2):312-8. PubMed ID: 17668858
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
Chintagumpala M; Hassall T; Palmer S; Ashley D; Wallace D; Kasow K; Merchant TE; Krasin MJ; Dauser R; Boop F; Krance R; Woo S; Cheuk R; Lau C; Gilbertson R; Gajjar A
Neuro Oncol; 2009 Feb; 11(1):33-40. PubMed ID: 18796696
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.
Pérez-Martínez A; Lassaletta A; González-Vicent M; Sevilla J; Díaz MA; Madero L
J Neurooncol; 2005 Jan; 71(1):33-8. PubMed ID: 15719272
[TBL] [Abstract][Full Text] [Related]
11. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
12. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
13. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
14. Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy.
Jennings MT; Cmelak A; Johnson MD; Moots PL; Pais R; Shyr Y
Pediatr Blood Cancer; 2004 Jul; 43(1):46-54. PubMed ID: 15170889
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.
Chi SN; Gardner SL; Levy AS; Knopp EA; Miller DC; Wisoff JH; Weiner HL; Finlay JL
J Clin Oncol; 2004 Dec; 22(24):4881-7. PubMed ID: 15611503
[TBL] [Abstract][Full Text] [Related]
16. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study.
Prados MD; Edwards MS; Chang SM; Russo C; Davis R; Rabbitt J; Page M; Lamborn K; Wara WM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):279-85. PubMed ID: 10030250
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors.
Choi LM; Rood B; Kamani N; La Fond D; Packer RJ; Santi MR; Macdonald TJ
Pediatr Blood Cancer; 2008 May; 50(5):970-5. PubMed ID: 17941070
[TBL] [Abstract][Full Text] [Related]
18. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.
Massimino M; Gandola L; Spreafico F; Luksch R; Collini P; Giangaspero F; Simonetti F; Casanova M; Cefalo G; Pignoli E; Ferrari A; Terenziani M; Podda M; Meazza C; Polastri D; Poggi G; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1031-7. PubMed ID: 16343801
[TBL] [Abstract][Full Text] [Related]
19. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.
Packer RJ; Sutton LN; Elterman R; Lange B; Goldwein J; Nicholson HS; Mulne L; Boyett J; D'Angio G; Wechsler-Jentzsch K
J Neurosurg; 1994 Nov; 81(5):690-8. PubMed ID: 7931615
[TBL] [Abstract][Full Text] [Related]
20. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
